HCV Detection Kit Dual Epitope Antibody Strategy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) detection methods face challenges such as the 'window phase' in antibody testing, where infections go undetected, and the complexity and cost of nucleic acid testing, which requires specialized training and equipment, limiting their effectiveness and accessibility.
Innovation Solution
A hepatitis C virus detection kit utilizing monoclonal antibodies specific to epitope regions 95-117 and 55-72 of the HCV core antigen, allowing for simultaneous detection of antigens and antibodies with improved sensitivity, stability, and reduced reaction time, suitable for rapid diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If HCV antibody testing is used for detection, then the method is simple and commonly available, but there is a window phase of 40-70 days where infections go undetected
Solution Approach 1:
The patent combines HCV antibody detection and HCV core antigen detection into a single dual-detection kit. The kit simultaneously detects both antibodies (indicating past exposure) and core antigens (indicating active infection), thereby eliminating the window phase limitation of antibody-only testing while maintaining operational simplicity.
2Measurement precision
If HCV nucleic acid testing is used for detection, then the detection accuracy and early stage detection capability are improved, but the operation complexity and cost increase significantly
Solution Approach 1:
The patent employs a disposable immunochromatographic test strip that integrates both antibody and core antigen detection capabilities. This single-use strip eliminates the need for complex PCR equipment, specialized training, and expensive nucleic acid extraction procedures, making high-accuracy detection accessible in general hospitals and blood stations.
3Loss of time
If HCV core antigen testing is used alone, then the window phase is shortened compared to antibody testing, but the detection sensitivity is insufficient for early stage infections
Solution Approach 1:
The dual-detection system combines core antigen detection (which appears early at 1-2 days) with antibody detection (which provides confirmatory evidence). This combination maintains the early detection advantage of antigen testing while improving overall sensitivity through the complementary information from antibody detection, reducing false negatives in early-stage infections.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit significantly shortens the window phase, enhances detection sensitivity, and reduces the risk of missing infections, while being more accessible and cost-effective, enabling early-stage acute hepatitis C diagnosis.
Implementation Method 1
monoclonal antibodies specific to epitope regions 95-117 and 55-72 of the HCV core antigen
Data Source
AI summary
Provided is a hepatitis C virus detection kit, a method for detecting hepatitis C virus, and a method for preparing a reagent or kit for detecting the hepatitis C virus. The kit contains a primary antibody and a second antibody for detecting a hepatitis C virus core antigen, wherein the primary antibody is directed against an epitope in a 95th-117th amino acid sequence of the hepatitis C virus core antigen or specifically binds to the 95th-117th amino acid sequence of the hepatitis C virus core antigen; and the second antibody is directed against an epitope in a 55th-72nd amino acid sequence of the hepatitis C virus core antigen or specifically binds to the 55th-72nd amino acid sequence of the hepatitis C virus core antigen. The kit has high sensitivity, good stability, and simple operation, and can be used for rapid detection of early acute hepatitis C.